Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: Usefulness in renal lithiasis treatment

Anticancer Research

Volumn 19, Issue 5 A, 1999, Pages 3717-3722

  Grases, Felix ^a   Costa Bauzá, Antonia ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Crystallization inhibitor; Pathological mineralization; Phytate; Renal calculi

Indexed keywords

CALCIUM SALT; PHYTATE;

CALCIFICATION; CALCIUM OXALATE STONE; CONFERENCE PAPER; HUMAN; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCINOSIS; HUMANS; KIDNEY CALCULI; PHYTIC ACID;

EID: 0032805781     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Bliznakov G: Sur le mecanisme de l'action des additifs adsorbants dans la croissance cristalline. In: Adsorption et Croissance Cristalline (Centre National de la Recherche Scientifique Ed.), Paris, 1965, pp. 291-301.
2. Fleisch H and Bisaz S: Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203: 671-675, 1962.
3. Fleisch H and Bisaz S: The inhibitory effect of pyrophosphate on calcium oxalate precipitation and its relation to urolithiasis. Experientia 20: 276-280, 1964.
4. Cramer W: Experimental production of kidney lesions by diet. Lancet 11: 174- 175, 1932.
5. Li MK, Blacklock NJ and Garside J: Effects of magnesium on calcium oxalate crystallization. J Urol 133: 123-125, 1985.
6. Hastings AB, McLean FC, Eichelberger L, Hall JL and Da Costa E: The ionization of calcium, magnesium and strontium citrates. J Biol Chem 107: 351-370, 1934.
7. Ryall RL, Harnett RM and Marshal VR: The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 112: 349-356, 1981.
8. Pak CYC: Citrate and renal calculi. Miner Electrolyte Metab 13: 257-266, 1987.
9. Crawford JE, Crematy EP and Alexander AE. The effect of natural and synthetic polyelectrolytes on the crystallization of calcium oxalate. Aust J Chem 21: 1067-1072, 1968.
10. Shum DK and Gohel MD: Separate effects of urinary chondroitin sulphate and heparan sulphate upon the crystallization of urinary calcium oxalate:differences between stone formers and normal controls. Clin Sci 85: 33-39, 1993.
11. Hess B: The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microsc 5: 689-696, 1991.
12. Hess B: Tamm-Horsfall glycoprotein-inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 20: 83-86, 1992.
13. Nakagawa Y, Margolis HC, Yokoyama S, Kezdy FJ, Kaiser ET and Coe FL: Purification and characterization of a calcium oxalate crystal growth inhibitor from human kidney tissue culture medium. J Biol Chem 256: 3936-3944, 1981.
14. Nakagawa Y, Abram V and Coe FL: Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine. Am J Physiol 247: F765-F772, 1984.
15. Hoyer JR: Uropontin in urinary calcium stone formation. Miner Electrolyte Metab 20: 385-392, 1995.
16. Barker LM, McPhillips JJ, Lawrence GD, Doty SB, Pallante SL, Bills CE, Scott WW and Howard JE: Studies on mechanisms of calcification. I. Properties of urinary derivatives which inhibits cartilage calcification. II. Electron microscopic observations of the effect of inhibitors in crystal formation. Johns Hopkins Med 127: 2-22, 1970.
17. Sallis JD, Parry NFG, Meehan JD, Kumperman H and Anderson ME: Controlling influence of phosphocitrate in vitro and in vivo on calcium oxalate crystal formation and growth. Scanning Microsc 9: 127-136, 1995.
18. Nakagawa Y, Abram V, Kezdy FJ, Kaiser ET and Coe FL: Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem 258: 12594-12600, 1983.
19. Dussol B and Berland Y: Urinary kidney stone inhibitors. Where are we? Nephrol Dial Transplant 11: 1222-1224, 1996.
20. Ryall RL: Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol 15: 155-164, 1997.
21. See WA and Williams RD: Urothelial injury and clotting cascade activation: common denominators in particulate adherence to urothelial surfaces. J Urol 147: 541-548, 1992.
22. Grases F, Garcia-Ferragut L and Costa-Bauzá A: Study of the early stages of renal stone formation: experimental model using urothelium of pig urinary bladder. Urol Res 24: 305-311, 1996.
23. French PJ, Bunce CM, Stephens LR, Lord JM, McConnell FM, Brown G, Creba JA and Michell RH: Changes in the levels of inositol lipids and phosphates during the differentiation of HL60 promyclocytic cells towards neutrophils or monocytes. Proc R Soc Lond B Biol Sci 245: 193-201, 1991.
24. Bunce CM, French PJ, Allen P, Mountford JC, Moor B, Greaves MF, Michell RH and Brown G: Comparison of the levels of inositol metabolites in transformed haemopoietic cells and their normal counterparts. Biochem J 289: 667-673, 1943.
25. Grases F and Llobera A: Determination of phytic acid in urine by ICP Atomic Emission Spectrometry. Anal Letts 29: 1193-1199, 1996.
26. March JG, Simonet BM, Grases F and Salvador A: Indirect determination of phytic acid in urine. Anal Chim Acta 367: 36-38, 1998.
27. Grases F, Costa-Bauzá A and Garcia-Ferragut L: Biopathological crystallization: a general view ahout the mechanisms of stone formation. Adv Colloid Interface Sci 74: 169-194, 1998.
28. Grases F, Costa-Bauzá A and March JG: Artificial simulation of the early stages of renal stone formation. Brit J Urol 74: 298-301, 1994.
29. Grases F, Garcia-Ferragut L, Costa-Bauzá A and March JG: Study of the effects of different substances on the early stages of papillary stone formation. Nephron 73: 561-568, 1996.
30. Grases F, Garcia-Ferragut L and Costa-Bauza A: Development of calcium oxalate crystals on urothelium: effect of tree radicals. Nephron 78: 296-301, 1998.
31. Grases F, Garcia-Gonzalez R, Torres JJ and Llobera A: The effects of phytic acid-Zn(II) mixtures on renal stone formation in rats. Scand J Urol Nephrol 31: 261-265, 1998.
32. Grases F, March JG, Prieto RM, Simonet BM, Garcia-Raja A and Conte A: Urinary phytate in calcium oxalate stone-formers and healthy people. Effects of diet on phytate excretion. Eu Urol, in press.
33. 6) in urine. Study of the relation between oral intake and urinary excretion. Brit J Urol, in press.
34. Conte A. Pizá P. Garcia-Raja A, Grases F, Costa-Bauzá A and Prieto RM: Test of urinary lithogen risk: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate). Arch Esp Urol, in press, 1999.
35. Grases F, García-Ferragut L, Costa-Bauzá A, Conte A and Garcia-Raja A: A simple test to evaluate the urinary risk of calcium stone formation. Clin Chim Acta 263: 43-55, 1997.
36. Henneman PH, Benedict PH, Forhes AP, Dudley HR. Idiopathic hypercalciuria. N Eng J Med 17: 802-807, 1958.
37. Vucenik I, Kalebic T, Tantivejkul K, Shamsuddin AM: Novel anticancer function of inositol hexaphosphate: Inhibition of human rhabdomyosarcoma in vitro and in vivo. Anticancer Res 18: 1377-1384, 1498.
38. 6, in HT-29 human colon carcinoma cell line. Anticancer Res 18: 1479-1484, 1498.
39. 6 in the treatment of liver cancer I. IP6 inhibits cell growth and reserves transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 18: 4083-4090, 1998.
40. 6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res 18: 4091-4096, 1998.
41. Graf E, Empson KL, Eaton JW: Phytic acid. A natural antioxidant. J Biol Chem 262: 11647-11650, 1987.